Fornier, Monica

Publications

Sort by

Co-Author Network

selected publications

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. NPJ breast cancer. 2019 Academic Article GET IT
Times cited: 12
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA dermatology. 2018 Academic Article GET IT
Times cited: 68
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 38
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. Journal of bone oncology. 2016 Academic Article GET IT
Times cited: 25
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2015 Academic Article GET IT
Times cited: 22
Denosumab and fracture risk in women with breast cancer. Lancet (London, England). 2015 Article GET IT
Times cited: 1
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
Atypical femur fractures associated with use of bisphosphonates and denosumab. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Article GET IT
Times cited: 7
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 71
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Molecular oncology. 2014 Academic Article GET IT
Times cited: 81
Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 2013 Information Resource GET IT
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 10
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer prevention research (Philadelphia, Pa.). 2013 Academic Article GET IT
Times cited: 60
Limited overall survival in patients with brain metastases from triple negative breast cancer. The breast journal. 2012 Academic Article GET IT
Times cited: 19
Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral diseases. 2012 Academic Article GET IT
Times cited: 51
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Academic Article GET IT
Times cited: 37
Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2012 Academic Article GET IT
Times cited: 12
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 51
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 69
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
Denosumab: second chapter in controlling bone metastases or a new book?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Editorial Article GET IT
Times cited: 15
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clinical breast cancer. 2010 Information Resource GET IT
Times cited: 5
HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park, N.Y.). 2010 Information Resource GET IT
Times cited: 35
Optimizing the use of anthracyclines in older patients with breast cancer. Critical reviews in oncology/hematology. 2010 Information Resource GET IT
Times cited: 2
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer immunology, immunotherapy : CII. 2010 Academic Article GET IT
Times cited: 16
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. International journal of radiation oncology, biology, physics. 2009 Academic Article GET IT
Times cited: 34
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of cancer research and clinical oncology. 2009 Academic Article GET IT
Times cited: 175
Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. Clinical advances in hematology & oncology : H&O. 2009 Academic Article GET IT
Times cited: 3
Novel anti-tubulin cytotoxic agents for breast cancer. Expert review of anticancer therapy. 2009 Information Resource GET IT
Times cited: 24
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anti-cancer drugs. 2009 Academic Article GET IT
Times cited: 1
Microtubule active agents: beyond the taxane frontier. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Information Resource GET IT
Times cited: 137
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 6
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008 Academic Article GET IT
Times cited: 82
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. The oncologist. 2008 Academic Article GET IT
Times cited: 103
Epothilones in breast cancer: current status and future directions. Expert review of anticancer therapy. 2008 Information Resource GET IT
Times cited: 10
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 48
Anabolic therapies for osteoporosis. The New England journal of medicine. 2007 Article GET IT
Times cited: 6
Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clinical breast cancer. 2007 Information Resource GET IT
Times cited: 22
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 74
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast cancer research and treatment. 2007 Information Resource GET IT
Times cited: 120
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 264
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. Anti-cancer drugs. 2007 Academic Article GET IT
Times cited: 6
Long-term clinical outcomes of whole-breast irradiation delivered in the prone position. International journal of radiation oncology, biology, physics. 2007 Academic Article GET IT
Times cited: 77
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 9
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anti-cancer drugs. 2006 Academic Article GET IT
Times cited: 5
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 70
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 188
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast cancer research and treatment. 2006 Academic Article GET IT
Times cited: 74
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005 Academic Article GET IT
Times cited: 152
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast cancer research : BCR. 2005 Academic Article GET IT
Times cited: 139
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Academic Article GET IT
Times cited: 105
Adjuvant chemotherapy for primary breast cancer. Current oncology reports. 2005 Information Resource GET IT
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 28
Risk models for neutropenia in patients with breast cancer. Oncology (Williston Park, N.Y.). 2003 Information Resource GET IT
Times cited: 3
HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park, N.Y.). 2002 Information Resource GET IT
Times cited: 64
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review). International journal of oncology. 2002 Information Resource GET IT
Times cited: 7
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 29
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 530
"Postpsychotic depression" and residual schizophrenia in a mental health hospital. L'Encephale. 2000 Academic Article GET IT
Times cited: 7
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer research. 1999 Academic Article GET IT
Times cited: 84
Update on the management of advanced breast cancer. Oncology (Williston Park, N.Y.). 1999 Information Resource GET IT
Times cited: 37
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 49
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. The International journal of biological markers. 1999 Academic Article GET IT
Times cited: 14
Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Progress in neuro-psychopharmacology & biological psychiatry. 1999 Academic Article GET IT
Times cited: 17
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. European journal of haematology. 1998 Academic Article GET IT
Times cited: 25
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. British journal of cancer. 1998 Academic Article GET IT
Times cited: 33
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 37
Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. Acta haematologica. 1997 Academic Article GET IT
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 20
Chronic myeloid leukemia treated with busulfan. Oncology reports. 1996 Academic Article GET IT
Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy. Oncology reports. 1996 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., University of Milan Faculty of Medicine and Surgery (Italy) 1992

Contact

full name

Monica Fornier

VIVO Weill Cornell Medical College

Monica Fornier Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name